Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.
Science Translational Medicine|April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapyPavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Research Square|November 28, 2024
Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinomaSangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Nature Communications|February 21, 2025
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trialSangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Cancer|December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.
Cancer Discovery|November 10, 2018
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Guillermo Garcia-Manero, Sreyashi Basu, et al.
Nature Communications|May 7, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trialPadmanee Sharma, Michael Krainer, Fred Saad, et al.
The Lancet. Gastroenterology & Hepatology|January 22, 2022
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trialAhmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.
Pageof 6